Soitec SA vs Chemours: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Soitec SA (SOI.PA)

Q3 202629 Jun – 18 Sep 2026

▲3▼2

AI demand hopes lift Soitec, then safety fears and tax hit drag it down

ZenSemi 300mm BCD-on-SOI partnership Soitec will supply Power-SOI substrates to ZenSemi for high-volume 300mm BCD-on-SOI production, targeting AI datacenters, EVs and robots. This adds a new customer and supports demand for Soitec's engineered substrates, a positive for future revenue.
New partnership directly expands demand for Soitec's core products.
Q2 revenue beat and raised guidance Soitec's Q2 revenue beat estimates by nearly 22%, and it later upgraded Q2 revenue growth guidance to around 50% year-on-year, driven by Photonics-SOI demand for AI data centers. Strong results and guidance support the stock.
Earnings beat and guidance raise are key positive fundamentals for the stock.
French tax dispute settlement Soitec agreed to settle a French tax dispute, forfeiting €320 million in tax loss carry-forwards and paying up to €60 million cash in Q3 2027. This reduces future cash tax savings and is a financial negative.
Settlement has a direct negative impact on Soitec's financials.
AI slowdown fears hit chip stocks AI leaders called for slower development, triggering a sharp sell-off in chip stocks. Soitec fell 12.6% as investors worried that slower AI buildout would cut demand for its Photonics-SOI products used in AI data centers.
This is the main negative driver this period, directly hitting Soitec's AI-linked demand outlook.
€500 million ORNANE bond issue Soitec raised €500 million in convertible bonds due 2033 at a low 0.5% coupon, with conversion price at a 55% premium. Proceeds will refinance debt and fund growth, showing investor confidence in its AI-related Photonics-SOI technology.
New financing strengthens balance sheet and signals confidence, a positive for the stock.

August 202629 Jun – 18 Sep 2026

▲3▼2

AI demand hopes lift Soitec, then safety fears and tax hit drag it down

ZenSemi 300mm BCD-on-SOI partnership Soitec will supply Power-SOI substrates to ZenSemi for high-volume 300mm BCD-on-SOI production, targeting AI datacenters, EVs and robots. This adds a new customer and supports demand for Soitec's engineered substrates, a positive for future revenue.
New partnership directly expands demand for Soitec's core products.
Q2 revenue beat and raised guidance Soitec's Q2 revenue beat estimates by nearly 22%, and it later upgraded Q2 revenue growth guidance to around 50% year-on-year, driven by Photonics-SOI demand for AI data centers. Strong results and guidance support the stock.
Earnings beat and guidance raise are key positive fundamentals for the stock.
French tax dispute settlement Soitec agreed to settle a French tax dispute, forfeiting €320 million in tax loss carry-forwards and paying up to €60 million cash in Q3 2027. This reduces future cash tax savings and is a financial negative.
Settlement has a direct negative impact on Soitec's financials.
AI slowdown fears hit chip stocks AI leaders called for slower development, triggering a sharp sell-off in chip stocks. Soitec fell 12.6% as investors worried that slower AI buildout would cut demand for its Photonics-SOI products used in AI data centers.
This is the main negative driver this period, directly hitting Soitec's AI-linked demand outlook.
€500 million ORNANE bond issue Soitec raised €500 million in convertible bonds due 2033 at a low 0.5% coupon, with conversion price at a 55% premium. Proceeds will refinance debt and fund growth, showing investor confidence in its AI-related Photonics-SOI technology.
New financing strengthens balance sheet and signals confidence, a positive for the stock.

Latest29 Jun – 18 Sep 2026

▲3▼2

AI demand hopes lift Soitec, then safety fears and tax hit drag it down

ZenSemi 300mm BCD-on-SOI partnership Soitec will supply Power-SOI substrates to ZenSemi for high-volume 300mm BCD-on-SOI production, targeting AI datacenters, EVs and robots. This adds a new customer and supports demand for Soitec's engineered substrates, a positive for future revenue.
New partnership directly expands demand for Soitec's core products.
Q2 revenue beat and raised guidance Soitec's Q2 revenue beat estimates by nearly 22%, and it later upgraded Q2 revenue growth guidance to around 50% year-on-year, driven by Photonics-SOI demand for AI data centers. Strong results and guidance support the stock.
Earnings beat and guidance raise are key positive fundamentals for the stock.
French tax dispute settlement Soitec agreed to settle a French tax dispute, forfeiting €320 million in tax loss carry-forwards and paying up to €60 million cash in Q3 2027. This reduces future cash tax savings and is a financial negative.
Settlement has a direct negative impact on Soitec's financials.
AI slowdown fears hit chip stocks AI leaders called for slower development, triggering a sharp sell-off in chip stocks. Soitec fell 12.6% as investors worried that slower AI buildout would cut demand for its Photonics-SOI products used in AI data centers.
This is the main negative driver this period, directly hitting Soitec's AI-linked demand outlook.
€500 million ORNANE bond issue Soitec raised €500 million in convertible bonds due 2033 at a low 0.5% coupon, with conversion price at a 55% premium. Proceeds will refinance debt and fund growth, showing investor confidence in its AI-related Photonics-SOI technology.
New financing strengthens balance sheet and signals confidence, a positive for the stock.

Chemours Co (CC)

Q3 202624 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.

July 202624 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.

Latest24 Jun – 7 Aug 2026

▲2▼2

Chemours settles PFAS suits, sets 2026 guidance; new state lawsuits add risk

EPA PFAS settlement removes major regulatory overhang Chemours agreed to pay a $22.5 million penalty and fund $90 million in PFAS mitigation projects, resolving a major federal dispute. The stock jumped 6.1% on the news as investors saw the settlement as a known cost that clears a big legal cloud, making future cash flows more predictable.
This is the period's biggest positive catalyst, directly lifting CC shares by reducing uncertainty.
New York and other states sue over PFAS contamination New York State sued 3M, DuPont, and Chemours spinoffs over PFAS, seeking cleanup costs and penalties. This adds fresh legal risk and potential future payouts, which can weigh on CC's stock because investors worry about unknown liabilities and cash outflows.
It introduces a new legal threat that could increase costs and uncertainty for CC.
2026 guidance shows earnings growth and deleveraging Chemours guided 2026 adjusted EBITDA to $775–$825 million and net leverage to about 3.8x, with Q2 beating expectations on pricing strength and cost cuts. This signals improving profits and a stronger balance sheet, supporting a higher stock price as investors gain confidence in the business.
It provides a forward-looking financial picture that directly influences CC's valuation.
Court approves $2.5 billion New Jersey PFAS settlements A federal judge approved over $2.5 billion in PFAS settlements involving DuPont, 3M, Chemours, and Corteva. While this resolves some claims, it confirms large legacy costs for Chemours, which can pressure the stock as investors factor in the cash outflows.
It finalizes a major liability that affects CC's financial obligations and investor sentiment.